Skip to content

Ketamine: all studies

Page 408 of 449: studies 4,071 to 4,080 of 4,483, newest first. Back to the ketamine overview

Research

Mapping Pharmacologically-induced Functional Reorganisation onto the Brain’s Neurotransmitter Landscape

bioRxiv (Cold Spring Harbor Laboratory) July 13, 2022 Andrea I. Luppi, Justine Y. Hansen, Ram Adapa et al. 5 citations preprint

Abstract To understand how pharmacological interventions can exert their powerful effects on brain function, we need to understand how they engage the brain’s rich neurotransmitter landscape. Here, we bridge microscale molecular chemoarchitecture and pharmacologically-induced macroscale functional reorganisation, by relating the regional distribution of 19 neurotransmitter receptors and...

DOI: 10.1101/2022.07.12.499688 (opens in new tab) Full text (opens in new tab) Neurotransmitter receptor Neurotransmitter systems Pharmacology

Обґрунтування можливості використання психофармакотерапевтичних методів для подолання негативного впливу російської війни на психічне здоров’я населення

Insight the psychological dimensions of society July 12, 2022 Олег Вікторович Орлов 1 citation

Метою дослідження є характеристика методу РАТ (Psychedeilc Assisted Therapy) та окреслення перспектив його впровадження в Україні. Методологія та методи. Використано методи теоретичного аналізування наукової літератури. Результати. З’ясовано, що за попередніми оцінками, щонайменше 23.5 млн. українських громадян ризикують зустрітися з погіршенням психічного здоров’я: до 20.0% з них – середнього...

Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review

Frontiers in Psychiatry July 12, 2022 Kwonmok Ko, Gemma Knight, James Rucker et al. 296 citations

The mystical experience is a potential psychological mechanism to influence outcome in psychedelic therapy. It includes features such as oceanic boundlessness, ego dissolution, and universal interconnectedness, which have been closely linked to both symptom reduction and improved quality of life. In this review, 12 studies of psychedelic therapy utilizing psilocybin, ayahuasca, or ketamine were...

DOI: 10.3389/fpsyt.2022.917199 (opens in new tab) Anxiety Clinical psychology Psychotherapist Distress

Pharmacotherapy for the Secondary Prevention of Suicide: Leads from the Social Pain Hypothesis

Preprints.org July 5, 2022 Ravi Philip Rajkumar 1 citation preprint

Suicidal behaviour is a public health problem whose magnitude is both substantial and increasing. Since many individuals seek medical treatment following a suicide attempt, strategies aimed at reducing further attempts in this population are a valid and feasible secondary prevention approach. An evaluation of the available evidence suggests that existing treatment approaches have limited...

DOI: 10.20944/preprints202207.0064.v1 (opens in new tab) Suicidal ideation Psychological pain Population Suicide prevention +5

Psychedelics in the treatment of unipolar and bipolar depression

International Journal of Bipolar Disorders July 5, 2022 Oliver G. Bosch, Simon Halm, Erich Seifritz 35 citations

Abstract This is a narrative review about the role of classic and two atypical psychedelics in the treatment of unipolar and bipolar depression. Since the 1990s, psychedelics experience a renaissance in biomedical research. The so-called classic psychedelics include lysergic acid diethylamide (LSD), psilocybin, mescaline and ayahuasca. Characteristic effects like alterations in sensory...

N-methyl-D-aspartate receptor antagonism impairs sensory gating in the auditory cortex in response to speech stimuli.

Psychopharmacology July 2022 Sara de la Salle, Joëlle Choueiry, Judy F McIntosh et al.

Deficits in early auditory sensory processing in schizophrenia have been linked to N-methyl-D-aspartate receptor (NMDAR) hypofunction, but the role of NMDARs in aberrant auditory sensory gating (SG) in this disorder is unclear. This study, conducted in 22 healthy humans, examined the acute effects of a subanesthetic dose of the NMDAR antagonist ketamine on SG as measured electrophysiologically...

DOI: 10.1007/s00213-022-06090-z (opens in new tab) Full text (opens in new tab) Auditory sensory gating N-methyl-d-aspartate receptor nmdar Schizophrenia Symptomatology

Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary review.

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy July 2022 Thomas J Moore, Abdallah Alami, G Caleb Alexander et al.

Ketamine, an anesthetic available since 1970, and esketamine, its newer S-enantiomer, provide a novel approach for the treatment of depression and other psychiatric disorders. At subanesthetic doses, the two drugs, along with their older congener, phencyclidine (PCP), induce a transient, altered mental state by blocking the N-methyl-D-aspartate (NMDA) receptor for glutamate, the primary...

DOI: 10.1002/phar.2707 (opens in new tab) Full text (opens in new tab) Esketamine Drug approval Evidence-based toxicology Ketamine hydrochloride +1

Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research

Addiction Neuroscience June 22, 2022 Fúlvio Rieli Mendes, Cristiane Dos Santos Costa, Victor Distefano Wiltenburg et al. 55 citations

Substance use disorder (SUD) is a global public health concern that affects millions of people worldwide. Considering current research, addiction has been noted as the last stage of a chronic disease that may impair brain reward circuit responses and affects personal and social life. Treatments for SUD face challenges including availability and limited pharmacological response, often resulting...

β-carboline-independent antidepressant-like effect of the standardized extract of the barks of Mimosa tenuiflora (Willd) Poir. occurs via 5-HT2A/2C receptors in mice

Journal of Psychopharmacology June 20, 2022 Luiz Antonio Miranda de Souza Duarte Filho, Isabela Araújo E Amariz, Rodolfo Hideki Vicente Nishimura et al. 12 citations

Background: Depression is a psychiatric disorder with limited therapy options. Psychedelics are new antidepressant candidates, being the ayahuasca one of the most promising ones. A synergistic combination of N,N-dimethyltryptamine (DMT) and β-carbolines allows ayahuasca antidepressant properties. Another psychedelic and DMT-containing beverage is the jurema wine used religiously by indigenous...

DOI: 10.1177/02698811221104050 (opens in new tab) Antidepressant Traditional medicine Pharmacology Receptor

Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions

Journal of Psychedelic Studies June 9, 2022 Annie M. Mccartney, Hugh McGovern, Alexander de Foe 8 citations

Abstract Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolonged effects on mood and cognition. The current body of psychedelic research has focused on administration and treatment within a psychiatric context. Here, instead, we put to the test the contention that it is necessary to evaluate the current state...